$CATX
Perspective Therapeutics Inc

2019 Q3 Form 10-K Financial Statement

#000143774919019176 Filed on September 27, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q2 2018 Q1
Revenue $2.315M $1.603M $1.573M
YoY Change 48.21% 17.01% 22.7%
Cost Of Revenue $1.079M $1.170M $964.0K
YoY Change 3.95% 34.48% -2.53%
Gross Profit $1.236M $443.0K $609.0K
YoY Change 135.88% -11.04% 107.85%
Gross Profit Margin 53.39% 27.64% 38.72%
Selling, General & Admin $1.912M $2.240M $1.475M
YoY Change 17.88% 9.27% 8.86%
% of Gross Profit 154.69% 505.64% 242.2%
Research & Development $233.0K $570.0K $473.0K
YoY Change -44.52% 78.13% 44.65%
% of Gross Profit 18.85% 128.67% 77.67%
Depreciation & Amortization $38.00K $30.00K $30.00K
YoY Change 18.75% 0.0% -25.0%
% of Gross Profit 3.07% 6.77% 4.93%
Operating Expenses $2.072M $2.800M $1.948M
YoY Change 1.47% 18.64% 15.81%
Operating Profit -$836.0K -$2.357M -$1.339M
YoY Change -44.93% 26.58% -3.6%
Interest Expense $20.00K $10.00K $10.00K
YoY Change 100.0% -66.67% -66.67%
% of Operating Profit
Other Income/Expense, Net $20.00K $0.00 $7.000K
YoY Change 100.0% -100.0% -75.86%
Pretax Income -$816.0K -$2.360M -$1.330M
YoY Change -45.96% 26.88% -2.21%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$816.0K -$2.343M -$1.332M
YoY Change -45.89% 26.38% -2.06%
Net Earnings / Revenue -35.25% -146.16% -84.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$12.11K -$42.55K -$24.14K
COMMON SHARES
Basic Shares Outstanding 67.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.575M $3.430M $4.520M
YoY Change -50.22% -61.76% -56.58%
Cash & Equivalents $4.575M $2.600M $2.365M
Short-Term Investments $830.0K $2.150M
Other Short-Term Assets $209.0K $29.00K $380.0K
YoY Change -59.81% -3.33% 8.57%
Inventory $501.0K $494.0K $458.0K
Prepaid Expenses
Receivables $1.521M $1.190M $970.0K
Other Receivables $0.00 $41.00K $0.00
Total Short-Term Assets $6.806M $5.446M $6.325M
YoY Change -39.6% -47.08% -46.95%
LONG-TERM ASSETS
Property, Plant & Equipment $1.669M $1.311M $1.229M
YoY Change 19.73% 24.38% 21.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $151.0K $198.0K $192.0K
YoY Change -18.38% -13.91% -28.09%
Total Long-Term Assets $3.318M $2.009M $1.997M
YoY Change 59.83% 1.57% -1.04%
TOTAL ASSETS
Total Short-Term Assets $6.806M $5.446M $6.325M
Total Long-Term Assets $3.318M $2.009M $1.997M
Total Assets $10.12M $7.455M $8.322M
YoY Change -24.13% -39.24% -40.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $984.0K $1.390M $770.0K
YoY Change -15.9% 120.63% 8.45%
Accrued Expenses $682.0K $440.0K $350.0K
YoY Change 45.11% -8.33% -18.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.666M $1.835M $1.123M
YoY Change 1.77% 65.91% -1.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.503M $590.0K $580.0K
YoY Change 150.5% 5.36% 5.45%
Total Long-Term Liabilities $1.503M $590.0K $580.0K
YoY Change 150.5% 5.36% 5.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.666M $1.835M $1.123M
Total Long-Term Liabilities $1.503M $590.0K $580.0K
Total Liabilities $3.169M $2.425M $1.706M
YoY Change 41.79% 45.47% 0.71%
SHAREHOLDERS EQUITY
Retained Earnings -$85.31M -$79.35M -$76.95M
YoY Change 5.51% 9.29% 8.76%
Common Stock $92.26M $84.38M $83.56M
YoY Change 0.32% 1.41% 0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.955M $5.030M $6.616M
YoY Change
Total Liabilities & Shareholders Equity $10.12M $7.455M $8.322M
YoY Change -24.13% -39.24% -40.31%

Cashflow Statement

Concept 2019 Q3 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$816.0K -$2.343M -$1.332M
YoY Change -45.89% 26.38% -2.06%
Depreciation, Depletion And Amortization $38.00K $30.00K $30.00K
YoY Change 18.75% 0.0% -25.0%
Cash From Operating Activities -$653.0K -$1.450M -$1.080M
YoY Change -59.49% 19.83% -27.52%
INVESTING ACTIVITIES
Capital Expenditures $98.00K -$130.0K -$80.00K
YoY Change -14.04% -43.48% 60.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.320M $580.0K
YoY Change -100.0% -42.11% -2033.33%
Cash From Investing Activities -$98.00K $1.200M $500.0K
YoY Change -98.44% -41.18% -725.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 480.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -653.0K -1.450M -1.080M
Cash From Investing Activities -98.00K 1.200M 500.0K
Cash From Financing Activities 480.0K 0.000
Net Change In Cash -751.0K 230.0K -580.0K
YoY Change 84.52% -72.29% -63.06%
FREE CASH FLOW
Cash From Operating Activities -$653.0K -$1.450M -$1.080M
Capital Expenditures $98.00K -$130.0K -$80.00K
Free Cash Flow -$751.0K -$1.320M -$1.000M
YoY Change -56.49% 34.69% -30.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q4 dei Entity Public Float
EntityPublicFloat
20081002
CY2019 dei Entity Registrant Name
EntityRegistrantName
IsoRay, Inc.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000728387
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67388047
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 dei Trading Symbol
TradingSymbol
isr
CY2019Q2 isr Accrued Payroll And Related Taxes Current
AccruedPayrollAndRelatedTaxesCurrent
89000
CY2018Q2 isr Accrued Payroll And Related Taxes Current
AccruedPayrollAndRelatedTaxesCurrent
155000
CY2019Q2 isr Accrued Protocol Expense
AccruedProtocolExpense
133000
CY2018Q2 isr Accrued Protocol Expense
AccruedProtocolExpense
77000
CY2018 isr Adjustments To Additional Paid In Capital Sharebased Compensation Third Party Services
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationThirdPartyServices
203000
CY2018 isr Adoption Of Asu201609 Reclassification From Retained Earnings To Additional Paid In Capital
AdoptionOfASU201609ReclassificationFromRetainedEarningsToAdditionalPaidInCapital
CY2018 isr Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
0.01
CY2017 isr Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
0.94
CY2018 isr Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
0.28
CY2019 isr Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
0.76
CY2018Q2 isr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
250000
CY2017 isr Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
230087
CY2018 isr Class Of Warrant Or Right Issued For Services
ClassOfWarrantOrRightIssuedForServices
500000
CY2019 isr Class Of Warrant Or Right Issued For Services
ClassOfWarrantOrRightIssuedForServices
5830000
CY2018 isr Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2019 isr Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2019 isr Gain Loss On Change In Aro Estimate
GainLossOnChangeInAROEstimate
CY2018 isr Gain Loss On Change In Aro Estimate
GainLossOnChangeInAROEstimate
CY2017 isr Gain Loss On Change In Aro Estimate
GainLossOnChangeInAROEstimate
48000
CY2019 isr Income Tax Reconciliation Change In Estimate
IncomeTaxReconciliationChangeInEstimate
-178000
CY2018 isr Income Tax Reconciliation Change In Estimate
IncomeTaxReconciliationChangeInEstimate
CY2017 isr Income Tax Reconciliation Change In Estimate
IncomeTaxReconciliationChangeInEstimate
CY2019 isr Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
CY2018 isr Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
CY2017 isr Income Tax Reconciliation Change In Fair Value Of Warrants
IncomeTaxReconciliationChangeInFairValueOfWarrants
-9000
CY2019 isr Increase Decrease In Accrued Payroll And Related Taxes
IncreaseDecreaseInAccruedPayrollAndRelatedTaxes
-66000
CY2018 isr Increase Decrease In Accrued Payroll And Related Taxes
IncreaseDecreaseInAccruedPayrollAndRelatedTaxes
17000
CY2017 isr Increase Decrease In Accrued Payroll And Related Taxes
IncreaseDecreaseInAccruedPayrollAndRelatedTaxes
66000
CY2019 isr Increase Decrease In Accrued Protocol Expense
IncreaseDecreaseInAccruedProtocolExpense
56000
CY2018 isr Increase Decrease In Accrued Protocol Expense
IncreaseDecreaseInAccruedProtocolExpense
2000
CY2017 isr Increase Decrease In Accrued Protocol Expense
IncreaseDecreaseInAccruedProtocolExpense
-47000
CY2019 isr Increase Decrease In Accrued Vacation
IncreaseDecreaseInAccruedVacation
-33000
CY2018 isr Increase Decrease In Accrued Vacation
IncreaseDecreaseInAccruedVacation
37000
CY2017 isr Increase Decrease In Accrued Vacation
IncreaseDecreaseInAccruedVacation
27000
CY2019 isr Noncash Financing Activities Warrants Issued
NoncashFinancingActivitiesWarrantsIssued
163000
CY2018 isr Noncash Financing Activities Warrants Issued
NoncashFinancingActivitiesWarrantsIssued
CY2017 isr Noncash Financing Activities Warrants Issued
NoncashFinancingActivitiesWarrantsIssued
CY2015Q4 isr Purchase Agreement Period
PurchaseAgreementPeriod
P1Y
CY2019 isr Research And Development Collaboration Services Net Of Reimbursement
ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
45000
CY2018 isr Research And Development Collaboration Services Net Of Reimbursement
ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
395000
CY2017 isr Research And Development Collaboration Services Net Of Reimbursement
ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
194000
CY2019 isr Research And Development Proprietary Research And Development
ResearchAndDevelopmentProprietaryResearchAndDevelopment
1429000
CY2018 isr Research And Development Proprietary Research And Development
ResearchAndDevelopmentProprietaryResearchAndDevelopment
1351000
CY2017 isr Research And Development Proprietary Research And Development
ResearchAndDevelopmentProprietaryResearchAndDevelopment
771000
CY2019Q2 isr Return Policy Restocking Fee Percent
ReturnPolicyRestockingFeePercent
0.5
CY2017 isr Share Based Compensation Arrangement By Share Based Payment Award Options Voided
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVoided
1179164
CY2017 isr Sharebased Compensation Arrangements By Sharebased Payment Award Options Voided In Period Weighted Average Exercise Price
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsVoidedInPeriodWeightedAverageExercisePrice
0.94
CY2019Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
683000
CY2018Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1391000
CY2019Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
142000
CY2018Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
175000
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7370000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7671000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
92105000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
84322000
CY2019 us-gaap Adjustment For Amortization
AdjustmentForAmortization
50000
CY2018 us-gaap Adjustment For Amortization
AdjustmentForAmortization
50000
CY2017 us-gaap Adjustment For Amortization
AdjustmentForAmortization
45000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
372000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
404000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
420000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
420000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
404000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
372000
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
26000
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
26000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
45000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10784380
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4068905
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3438256
CY2018Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
590000
CY2017Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
561000
CY2019Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
621000
CY2019 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
31000
CY2018 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
29000
CY2017 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
29000
CY2019Q2 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
621000
CY2018Q2 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
590000
CY2018Q2 us-gaap Assets
Assets
7455000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
7315000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
5446000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5326000
CY2019Q2 us-gaap Assets
Assets
9422000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2600000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5932000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2781000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6113000
CY2016Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10320000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5507000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2726000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3332000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4207000
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.94
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.54
CY2019Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5830000
CY2019Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6080000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
230087
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
250000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67388047
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56331147
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67388047
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56331147
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
67000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
56000
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16248000
CY2018Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15020000
CY2019Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15207000
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14171000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4267000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4081000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3923000
CY2019Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6000
CY2018Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
10000
CY2019Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
204000
CY2018Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
197000
CY2019Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
96000
CY2018Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
578000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
480000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations
130000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations
124000
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
27000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
38000
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16248000
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15020000
CY2019 us-gaap Depreciation
Depreciation
136000
CY2018 us-gaap Depreciation
Depreciation
80000
CY2017 us-gaap Depreciation
Depreciation
68000
CY2017 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
11000
CY2018 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
11000
CY2019 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
11000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4172000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4165000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3920000
CY2019 us-gaap Gross Profit
GrossProfit
3047000
CY2018 us-gaap Gross Profit
GrossProfit
1842000
CY2017 us-gaap Gross Profit
GrossProfit
838000
CY2018Q3 us-gaap Gross Profit
GrossProfit
524000
CY2018Q4 us-gaap Gross Profit
GrossProfit
765000
CY2019Q1 us-gaap Gross Profit
GrossProfit
879000
CY2019Q2 us-gaap Gross Profit
GrossProfit
879000
CY2017Q3 us-gaap Gross Profit
GrossProfit
265000
CY2017Q4 us-gaap Gross Profit
GrossProfit
531000
CY2018Q1 us-gaap Gross Profit
GrossProfit
609000
CY2018Q2 us-gaap Gross Profit
GrossProfit
443000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.28
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
632000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y29D
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
810000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
778000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
32000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
38000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
23000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23000
CY2019Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
972000
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
976000
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
162000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
198000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
24000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
9500000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1228000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-7703000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2123000
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
9556000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1080000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1878000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2157000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
12000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
21000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
17000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
18000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
4000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
16000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
10000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-708000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
761000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-38000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
466000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
184000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-128000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-23000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-89000
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
37000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-88000
CY2017 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-52000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-30000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-100000
CY2019Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
31000
CY2018Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
27000
CY2019Q2 us-gaap Inventory Net
InventoryNet
530000
CY2018Q2 us-gaap Inventory Net
InventoryNet
494000
CY2019Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
155000
CY2018Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
319000
CY2019Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
166000
CY2018Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
96000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
108000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
118000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-1463000
CY2019Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
333000
CY2018Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
371000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
203000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019Q2 us-gaap Liabilities
Liabilities
1742000
CY2018Q2 us-gaap Liabilities
Liabilities
2425000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9422000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7455000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1121000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1835000
CY2019 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
210000
CY2018 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
329000
CY2017 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
323000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray, Inc. was incorporated in Minnesota in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1983.</div> On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 28, 2005, </div>Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018, </div>upon approval of a majority of shareholders, Isoray, Inc. was redomiciled to Delaware. Medical was formed under Delaware law on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 15, 2004 </div>and on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 1, 2004 </div>acquired <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> affiliated predecessor companies which began operations in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1998.</div> Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray International LLC (International), a Washington limited liability company, was formed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 27, 2007 </div>and is a wholly-owned subsidiary of Isoray, Inc. International has entered into various international distribution agreements.</div></div>
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7374000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
521000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
401000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1859000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1514000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5049000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5712000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5712000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-5144000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-6700000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-6162000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1508000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-1414000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1127000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1095000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-1546000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-5254000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-6729000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-6307000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
531000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
241000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
290000
CY2019Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
72400000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1332000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2343000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5155000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6711000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6173000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
110000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
145000
CY2019 us-gaap Open Tax Year
OpenTaxYear
2017 2018 2019
CY2019 us-gaap Operating Expenses
OperatingExpenses
8301000
CY2018 us-gaap Operating Expenses
OperatingExpenses
8571000
CY2017 us-gaap Operating Expenses
OperatingExpenses
7145000
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
27000
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
29000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
162000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74000
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
37000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2019Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
154000
CY2018Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
241000
CY2019Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
86000
CY2018Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
41000
CY2019 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
11000
CY2018 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
11000
CY2017 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
11000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14000
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
18000
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
124000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
444000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
337000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4725000
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4054000
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
115000
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11000
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11000
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7001671
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Prepaid Advertising
PrepaidAdvertising
9000
CY2018Q2 us-gaap Prepaid Advertising
PrepaidAdvertising
9000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
305000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
335000
CY2019Q2 us-gaap Prepaid Insurance
PrepaidInsurance
38000
CY2018Q2 us-gaap Prepaid Insurance
PrepaidInsurance
24000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
34000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
CY2019 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
5550000
CY2018 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
6268000
CY2017 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
2296000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8979000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8982000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1609000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1311000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-4000
CY2019Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1154000
CY2018Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1192000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1474000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1746000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
965000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
181000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
181000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
181000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
181000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84492000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79348000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7314000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5923000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4761000
CY2018Q3 us-gaap Revenues
Revenues
1562000
CY2018Q4 us-gaap Revenues
Revenues
1904000
CY2019Q1 us-gaap Revenues
Revenues
1924000
CY2019Q2 us-gaap Revenues
Revenues
1924000
CY2017Q3 us-gaap Revenues
Revenues
1211000
CY2017Q4 us-gaap Revenues
Revenues
1536000
CY2018Q1 us-gaap Revenues
Revenues
1573000
CY2018Q2 us-gaap Revenues
Revenues
1603000
CY2019 us-gaap Royalty Expense
RoyaltyExpense
285000
CY2018 us-gaap Royalty Expense
RoyaltyExpense
285000
CY2017 us-gaap Royalty Expense
RoyaltyExpense
288000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
509904
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
100000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
242000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
561541
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2679000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2660000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2310000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
420000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
404000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
372000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2153645
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.81
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
68125
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.54
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.61
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.47
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.44
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2150000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1125000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1252500
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.31
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.34
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.45
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
263000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
151000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2925059
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3379191
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3759840
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4645315
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.78
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.69
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.64
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4645315
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.64
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1252500
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1125000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2150000
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.26
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.61
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.26
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.55
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.75
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.41
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.77
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y277D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y339D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y313D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y273D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y346D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y346D
CY2019Q2 us-gaap Short Term Investments
ShortTermInvestments
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
825000
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55056000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55100000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55463000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6800
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
82810
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56900
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
479000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7370000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
7680000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
5030000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
16401000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
10602000
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
CY2018 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
CY2017 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
27000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company&#x2019;s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company&#x2019;s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</div></div></div></div></div></div>
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67042000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55159000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55016000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66147000
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67331000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67333000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67357000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55017000

Files In Submission

Name View Source Status
0001437749-19-019176-index-headers.html Edgar Link pending
0001437749-19-019176-index.html Edgar Link pending
0001437749-19-019176.txt Edgar Link pending
0001437749-19-019176-xbrl.zip Edgar Link pending
chart1.jpg Edgar Link pending
ex_158242.htm Edgar Link pending
ex_158243.htm Edgar Link pending
ex_158244.htm Edgar Link pending
ex_158245.htm Edgar Link pending
ex_158246.htm Edgar Link pending
ex_158247.htm Edgar Link pending
ex_158570.htm Edgar Link pending
ex_158727.htm Edgar Link pending
ex_158727img001.gif Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isr-20190630.xml Edgar Link completed
isr-20190630.xsd Edgar Link pending
isr-20190630_cal.xml Edgar Link unprocessable
isr-20190630_def.xml Edgar Link unprocessable
isr-20190630_lab.xml Edgar Link unprocessable
isr-20190630_pre.xml Edgar Link unprocessable
isr20190630_10k.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending